$Akero Therapeutics(AKRO.US)$MILWAUKEE, April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Akero (Nasdaq: AKRO). The investigation results from inaccurate statements Akero may have made regarding its business operations and prospects. Click here to learn more about the investigation: or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. The investigation focuses on Akero's representations...
Analysts tout Akero's data as potentially the best for MASH treatment. Jefferies' Michael Yee labels it as 'best-in-class and best-in-disease therapeutic', while Cantor Fitzgerald's Prakhar Agrawal believes it dispels concerns about competition from drugs like Lilly's tirzepatide.
Significant insider selling at Akero Therapeutics, Inc. is a cause for concern among investors, despite reasonable level of insider ownership. Due to this recent activity, the stock demands careful consideration before purchase.
Akero Therapeutics股票討論區
Click here to learn more about the investigation: or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
The investigation focuses on Akero's representations...
NASH Basket- $Madrigal Pharmaceuticals(MDGL.US)$ $Viking Therapeutics(VKTX.US)$ $Akero Therapeutics(AKRO.US)$ $89bio(ETNB.US)$
Than we already know how big Obesity market is going to be over next decade with global 1.5 Billion obese pts
Obesity Basket $Viking Therapeutics(VKTX.US)$ $禮來(LLY.US)$ $諾和諾德(NVO.US)$
$Leap Therapeutics(LPTX.US)$ Phase 2
$Vera Therapeutics(VERA.US)$ Phase 2b
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$Akero Therapeutics(AKRO.US)$ Phase 2b
$Spruce Biosciences(SPRB.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$阿里拉姆制藥(ALNY.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Annexon(ANNX.US)$ Phase 2a
$Roivant Sciences(ROIV.US)$...
暫無評論